Background {#Sec1}
==========

Myelosuppressive chemotherapy treatment commonly results in chemotherapy-induced neutropenia (CIN), a complication associated with a high risk of morbidity, mortality, and hospitalization \[[@CR1]\]. After a course of chemotherapy, the duration of neutropenia and depth of the absolute neutrophil count (ANC) at nadir, correlates with the development of infections including febrile neutropenia (FN), sepsis and their morbidities \[[@CR2], [@CR3]\].

Filgrastim, a granulocyte colony stimulating factor (G-CSF), stimulates hematopoietic cells, promoting growth, proliferation, differentiation, and maturation of neutrophil precursors. Filgrastim also enhances the function of mature neutrophils by increasing phagocytic activity and antibody-dependent cell-mediated cytotoxicity \[[@CR4], [@CR5]\].

The addition of a polyethylene glycol moiety to filgrastim results in the long-acting form of pegfilgrastim, which requires only once-per-cycle administration for CIN management. Pegfilgrastim retains the same biological activity as filgrastim and binds to the same G-CSF receptor. In both experimental animals and healthy human volunteers, pegfilgrastim showed decreased renal clearance and increased plasma half-life compared with unpegylated filgrastim, allowing pegfilgrastim a sustained pharmacological effect \[[@CR6]\]. In clinical trials, patients receiving pegfilgrastim experienced a lower incidence of FN than patients receiving filgrastim \[[@CR7]\].

Several international clinical guidelines \[European Organization for Research and Treatment of Cancer (EORTC), American Society for Clinical Oncology (ASCO), and National Comprehensive Cancer Network (NCCN)\] recommend prophylactic administration of G-CSF (filgrastim or pegfilgrastim) with chemotherapy associated with a high risk (\> 20%) of FN and supportive G-CSF therapy with chemotherapy regimens associated with intermediate frequency (10--20%) of FN when additional predisposing factors exist for the patient (e.g., age \> 65 years, experience of previous episode(s) of FN, or advanced stage of disease).

Apotex, Inc. and Intas Pharmaceuticals Limited have codeveloped a proposed pegfilgrastim biosimilar product to the US-licensed and EU-approved reference product Neulasta^®^, marketed by Amgen, Inc. State-of-the-art analytical techniques previously demonstrated analytical similarity between the proposed pegfilgrastim biosimilar and the US-licensed pegfilgrastim reference product \[[@CR8]\]. In addition, nonclinical primary pharmacodynamic (PD) repeat-dose toxicity/toxicokinetics, local tolerance studies, and a two-way cross-over Phase I pharmacokinetic/pharmacodynamic (PK/PD) study in healthy volunteers showing no unexpected safety events and no clinically relevant PK/PD differences between the proposed pegfilgrastim biosimilar and the US-licensed reference product provides further evidence supporting a conclusion that the proposed pegfilgrastim biosimilar is biosimilar to the reference product \[[@CR9]\].

This article presents evidence from a head-to-head clinical confirmatory study comparing efficacy and safety (including immunogenicity) of the proposed pegfilgrastim biosimilar with the reference product (commercially available US-licensed and EU-approved Neulasta^®^) in patients with early breast cancer receiving chemotherapy.

Methods {#Sec2}
=======

Patient eligibility {#Sec3}
-------------------

Female patients ≥ 18 years of age with Stage IIA, IIB or IIIA breast cancer, who were suitable and intended to undergo adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy were eligible for this study. Inclusion criteria included: patients within 60 days of complete surgical resection of the primary breast tumor, either lumpectomy or mastectomy, with sentinel lymph node biopsy or axillary dissection, with clear margins for both invasive and ductal carcinoma in situ (DCIS); Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; ANC ≥ 1.5 × 10^9^/L; platelet count ≥ 100 × 10^9^/L; adequate renal function (serum creatinine \< 1.5 × upper limit of normal \[ULN\]) and hepatic function (bilirubin \< ULN, transaminases and alkaline phosphatase \[AP\] \< 1.5 × ULN); normal cardiac function evidenced by a left ventricle ejection fraction (LVEF) ≥ 55%; no evidence of metastatic disease; and baseline bilateral mammography or other scan to exclude cancer on the contralateral breast. Patients were excluded if they had or received any of the following: (concomitant or prior) except in situ lesion, either ductal or lobular, of the contralateral breast; prior chemotherapy (either adjuvant or neoadjuvant) for this incidence of breast cancer; history of uncontrolled cardiac disease; immunotherapy, hormonal therapy (e.g., tamoxifen or aromatase inhibitors), or Herceptin^®^ (trastuzumab) concurrently or within 30 days of screening; concurrent radiation therapy; investigational therapy concurrently or within 30 days of screening; peripheral neuropathy \> Grade 1; major organ allograft or condition requiring chronic immunosuppression; or history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin, carcinoma in situ of uterine cervix, or DCIS).

Study design and treatment {#Sec4}
--------------------------

This was a confirmatory, randomized, controlled, assessor-blinded, multicenter study comparing efficacy and safety of the proposed pegfilgrastim biosimilar to the US-licensed pegfilgrastim reference product and the EU-approved pegfilgrastim reference product conducted in 11 Central and Eastern European countries. The study consisted of three phases: a screening period ≤ 3 weeks; an 18-week active treatment period including 6, 3-week cycles of TAC chemotherapy (docetaxel 75 mg/m^2^, doxorubicin 50 mg/m^2^, and cyclophosphamide 500 mg/m^2^); and a safety follow-up period ≤ 30 weeks following the completion of the TAC regimen. Eligible patients were randomized to either the proposed pegfilgrastim biosimilar (APO-Peg), US-licensed pegfilgrastim reference product (US-Neulasta^®^) or EU-approved pegfilgrastim reference product (EU-Neulasta^®^) in a 2:1:1 ratio. Premedication with dexamethasone and ondansetron was initiated before administration of each chemotherapy cycle. Each patient received 6 doses of pegfilgrastim (6 mg/0.6 mL pre-filled syringe for each) for each chemotherapy cycle, administered as subcutaneous injection on Day 2 of each cycle (at least 24 h after chemotherapy).

In Cycle 1, blood samples were collected for complete blood counts with differentials on Day 0, 1, 3, 5, 6, 7, and every day until ANC recovery post-nadir to ≥ 2.0 × 10^9^/L, or up to Day 15 if recovery did not occur earlier. Blood samples for ANC measurements in Cycles 2--6 were collected mainly to assess safety. Blood samples were collected during the screening, treatment, and follow-up periods for immunogenicity testing.

Assessments {#Sec5}
-----------

The primary efficacy endpoint was the duration of severe neutropenia (DSN), defined as ANC below 0.5 × 10^9^/L. Secondary endpoints included: depth and peak of ANC nadir in Cycle 1; time to the ANC recovery post-nadir in Cycle 1; rates of FN (defined as a single temperature ≥ 38.3 °C or temperature ≥ 38.0 °C for over 1 h and ANC less than 0.5 × 10^9^/L or less than 1 × 10^9^/L and predicted decline to ≤ 0.5 × 10^9^/L over the next 48 h) by cycle and across all cycles. Safety assessment included: the incidence of adverse events (AEs) classified by system organ class, preferred term, severity, and relationship to study medication; injection site reactions; vital signs; presence of antibodies to pegfilgrastim; and abnormal clinical laboratory results.

Statistical analyses {#Sec6}
--------------------

The inference for equivalence was based on the two-sided 95% confidence interval (CI) for the difference in means between the proposed pegfilgrastim biosimilar and the US-licensed or EU-approved pegfilgrastim reference product for DSN in Cycle 1 (in days). Equivalence was defined as a CI range of \[− 0.5 days, + 0.5 days\]. The two-sided 95% CIs were derived from a one-way ANOVA model accounting for the treatment effect. For statistical analyses, treatment groups were defined as follows:

*Full analysis set (FAS)-As Randomized* included all enrolled subjects who were randomized, received at least one dose of active treatment, and who had any follow-up data for the primary endpoint variables. Treatment assignment for subjects was based on the treatment they were randomized to (*As Randomized* allocation). *FAS-As Randomized* represents the prespecified primary analysis set used for efficacy endpoints.

*FAS-As Treated* included all enrolled subjects who were randomized and received at least one dose of active treatment, and who had any follow-up data for the primary endpoint variables. Treatment assignment for subjects was based on the treatment they received in each cycle instead of the treatment they were randomized to receive.

*Safety analysis set, sensitivity* included all subjects who received at least one dose of active treatment. All subjects who received APO-Peg at any time during the treatment period (regardless of randomized treatment group) were included in the APO-Peg group for this data set. Subjects who did not receive APO-Peg at any time were assigned to their randomized treatment group.

*Per protocol (PP) analysis set* included all enrolled subjects who were randomized and received at least one dose of active treatment, and who had any follow-up data for the primary endpoint variables. Subjects with protocol deviations that impacted the integrity of the primary endpoint data and the safety/well-being of the subject in Cycle 1 were excluded from the PP (Cycle 1) analysis for the primary endpoint. Additionally, subjects with protocol deviations affecting the integrity of the data and the endpoint of the efficacy/safety analysis and well-being of the subject during Cycles 2--6 were excluded from the PP (All Cycles) analyses.

Results {#Sec7}
=======

Patients {#Sec8}
--------

A total of 595 patients were randomized from 56 investigational centers in 11 countries. All subjects were suitable for neoadjuvant TAC treatment (all chemotherapy naïve subjects: 41.8% Stage IIa; 27.7% Stage 27.7%; and 30.6% Stage IIIa). Patient demographics and breast cancer history were consistent across the treatment arms (Table [1](#Tab1){ref-type="table"}). Of those randomized, 589 patients were dosed, with 547 (92.9%) completing 6 cycles of treatment and 42 (7.1%) discontinuing the study (Fig. [1](#Fig1){ref-type="fig"}). Some subjects who withdrew from the treatment phase were followed in the safety follow-up phase.Table 1Demographic and breast cancer history data---FAS (As Randomized)Proposed biosimilar pegfilgrastim (APO-Peg) (*N *= 294)US-licensed pegfilgrastim reference product (US-Neulasta^®^) (*N *= 148)EU-approved pegfilgrastim reference product (EU-Neulasta^®^) (*N *= 147)Total (*N *= 589)Demographic dataFemale, n (%)*294* (100)*148* (100)*147* (100)*589* (100) Age (years)  Mean (SD)51.9 (10.0)51.4 (10.4)51.5 (10.2)51.7 (10.1)  Median (min, max)52.0 (24.0, 75.0)52.0 (27.0, 80.0)53.0 (22.0, 77.0)52.0 (22.0, 80.0)Race, n (%) Caucasian*294* (100.0)*148* (100.0)*147* (100.0)*589* (100.0) Body weight (kg)  Mean (SD)73.88 (14.4)72.01 (14.1)72.61 (12.9)73.09 (14.0)  Median (min, max)73.0 (40.0, 120.0)70.0 (40.0, 118.0)70.0 (48.0, 119.0)72.0 (40.0, 120.0) Body height (cm)  Mean (SD)162.5 (6.8)162.7 (6.6)162.6 (6.4)162.6 (6.6)  Median (min, max)163.0 (140.0, 180.0)163.0 (142.0, 180.0)163.0 (148.0, 183.0)163.0 (140.0, 183.0) Breast cancer history  Tumor parameter   Staging IIA129 (43.9)59 (39.9)58 (39.5)246 (41.8)   Staging IIB79 (26.9)40 (27.0)44 (29.9)163 (27.7)   Staging IIIA86 (29.3)49 (33.1)45 (30.6)180 (30.6)T1, T2, T3 means the size and/or extent of the primary tumor stage (increasing order from 1 to 3) Fig. 1Disposition of patients as randomized: distribution of randomized patients into three arms (the proposed pegfilgrastim biosimilar, US-licensed pegfilgrastim reference product, an EU-approved pegfilgrastim reference product), including the number of patients that withdrew and completed treatment and safety follow up

Comparative efficacy {#Sec9}
--------------------

As a sensitive measure of efficacy \[[@CR10]\], the assessment of DSN in Cycle 1 (versus subsequent cycles) was chosen as the primary endpoint. Overall, the mean DSN in Cycle 1 is comparable across treatments and essentially the same between the FAS *As Treated* and *As Randomized* populations (Table [2](#Tab2){ref-type="table"}). For the *As Randomized* population, the 95% CI of the difference in mean DSN in Cycle 1 between the proposed pegfilgrastim biosimilar and US-licensed pegfilgrastim reference product was slightly outside the equivalence margin, but for the proposed pegfilgrastim biosimilar and EU-approved pegfilgrastim reference product was contained within the pre-defined margin (Table [2](#Tab2){ref-type="table"}). Given that sampling of ANC for determination of DSN in a clinical setting is conducted on a daily basis, as in this study, the breach of 0.01 days, which equates to approximately 14.4 min from the upper limit of the equivalence range (0.51 days), is not considered clinically significant. The results for the *As Treated* population showed a 95% CI within the equivalence range for the proposed pegfilgrastim biosimilar between both the US-licensed and EU-approved pegfilgrastim reference products, confirming similar efficacy (Table [2](#Tab2){ref-type="table"}).Table 2Summary of DSN in cycle 1 (FAS-As Randomized and FAS-As Treated)Analysis Set StatisticProposed biosimilar pegfilgrastim (APO-Peg)US-licensed pegfilgrastim reference product (US-Neulasta^®^)EU-approved pegfilgrastim reference product (EU-Neulasta^®^)(APO-Peg)-minus (US-Neulasta^®^)(APO-Peg)-minus (EU-Neulasta^®^)(EU-Neulasta^®^) minus (US-Neulasta^®^)FAS (As Randomized) N294148147N/AN/AN/A LS Mean in days1.61.41.60.20.020.2 Median (Min, Max) in days2.0 (0, 10)1.0 (0, 5)2.0 (0, 10)N/AN/AN/A 95% CI in days1.47 to 1.791.17 to 1.611.38 to 1.83− 0.03 to 0.51− 0.25 to 0.30− 0.10 to 0.53FAS (As Treated) N*298147144*N/AN/AN/A LS Mean in days1.61.41.60.2-0.010.2 Median (Min, Max) in days1.5 (0, 10)1.0 (0, 5)2.0 (0, 10)N/AN/AN/A 95% CI in days1.46 to 1.771.17 to 1.611.41 to 1.86− 0.04 to 0.50− 0.29 to 0.26− 0.07 to 0.56

Similarity between the proposed pegfilgrastim biosimilar and the EU-approved and US-licensed reference products was also supported by comparative results between all treatment arms for all secondary efficacy endpoints (Table [3](#Tab3){ref-type="table"} and data not shown). The rate of FN (*As Randomized*) was similar between treatment arms with the highest incidence occurring in Cycle 1 (as expected) and decreasing in subsequent treatment cycles (Table [3](#Tab3){ref-type="table"}). In addition, the mean ANC values showed similar results among the three treatment arms \[overall mean peak ANC of 28.9 × 10^9^/L (day 3.1--3.4); overall mean ANC nadir of 0.5 × 10^9^/L (day 7.1--7.3), and recovery of ANC (≥ 2.0 × 10^9^/L; day 9.2--9.5)\] (Table [4](#Tab4){ref-type="table"}).Table 3Rates of FN by cycle following treatment (FAS---As Randomized)CycleProposed biosimilar pegfilgrastim (APO-Peg)US-licensed pegfilgrastim reference product (US-Neulasta^®^)EU-approved pegfilgrastim reference product (EU-Neulasta^®^)TotalCycle 1 n/N (%)15/294 (5.1)6/148 (4.1)5/147 (3.4)26/589 (4.4) 95% CI2.9--8.31.5--8.61.1--7.82.9--6.4Cycle 2 n/N (%)0/288 (0.0)1/146 (0.7)0/144 (0.0)1/578 (0.2) 95% CI0.0--1.30.0--3.80.0--2.50.0--1.0Cycle 3 n/N (%)0/285 (0.0)0/146 (0.0)1/144 (0.7)1/575 (0.2) 95% CI0.0--1.30.0--2.50.0--3.80.0--1.0Cycle 4 n/N (%)0/284 (0.0)0/144 (0.0)0/144 (0.0)0/572 (0.0) 95% CI0.0--1.30.0--2.50.0--2.50.0--0.6Cycle 5 n/N (%)2/276 (0.7)0/143 (0.0)0/142 (0.0)2/561 (0.4) 95% CI0.1--2.60.0--2.50.0--2.60.0--1.3Cycle 6 n/N (%)0/270 (0.0)0/143 (0.0)0/139 (0.0)0/552 (0.0) 95% CI0.0--1.40.0--2.50.0--2.60.0--0.7Overall n/N (%)17/294 (5.8)7/148 (4.7)5/147 (3.4)29/589 (4.9) 95% CI3.4--9.11.9--9.51.1--7.83.3--7.0 Table 4Mean ANC values for planned sampling days in cycle 1 (FAS-As Randomized and FAS-As Treated)CharacteristicsProposed biosimilar pegfilgrastim (APO-Peg) *N *= 294US-licensed pegfilgrastim reference product (US-Neulasta^®^) *N *= 148EU-approved pegfilgrastim reference product (EU-Neulasta^®^) *N *= 147Total *N *= 589FAS-As Randomized Day on which the peak ANC value was reached  N294148147589  Mean (SD)3.4 (2.3)3.1 (0.6)3.1 (1.4)3.2 (1.8)  Median3.03.03.03.0  Minimum--maximum1--243--91--181--24  95% CIs of mean3.1--3.63.0--3.22.9--3.43.1--3.4 Peak ANC value (× 10^9^/L)  N294148147589  Mean (SD)28.4 (9.5)29.9 (10.2)28.7 (9.3)28.9 (9.6)  Median27.729.427.928.0  Minimum--maximum3.9--60.511.3--88.05.8--55.93.9--88.0  95% CIs of mean27.3--29.528.3--31.627.2--30.228.1--29.7 Day on which the depth of ANC nadir was reached  N294148147589  Mean (SD)7.1 (1.8)7.1 (0.6)7.3 (2.1)7.1 (1.7)  Median7.07.07.07.0  Minimum--maximum1--216--116--211--21  95% CIs of mean6.9--7.37.0--7.27.0--7.77.0--7.3 Depth of ANC nadir (× 10^9^/L)  N294148147589  Mean (SD)0.6 (1.1)0.4 (0.6)0.4 (0.7)0.5 (0.9)  Median0.20.20.10.2  Minimum--maximum0.0--9.80.0--3.40.0--6.00.0--9.8  95% CIs of mean0.4--0.70.3--0.50.3--0.50.4--0.6 Day on which recovery of ANC was reached  N267136137540  Mean (SD)9.4 (2.0)9.5 (2.1)9.2 (1.0)9.4 (1.8)  Median9.09.09.09.0  Minimum--maximum6--258--228--136--25  95% CIs of mean9.2--9.79.1--9.89.0--9.49.2--9.5CharacteristicsProposed biosimilar pegfilgrastim (APO-Peg) *N *= 298US-licensed pegfilgrastim reference product (US-Neulasta^®^) *N *= 147EU-approved pegfilgrastim reference product (EU-Neulasta^®^) *N *= 147Total\
*N *= 589FAS-As Treated Day on which the peak ANC value was reached  N298147144589  Mean (SD)3.4 (2.3)3.1 (0.5)3.1 (1.4)3.2 (1.8)  Median3.03.03.03.0  Minimum--maximum1--243--91--181--24  95% CIs of mean3.1--3.63.0--3.22.9--3.43.1--3.4Peak ANC value (× 10^9^/L)  N298147144589  Mean (SD)28.5 (9.6)29.7 (10.2)28.8 (9.2)28.9 (9.6)  Median27.728.628.328.0  Minimum--maximum3.9--60.511.3--88.05.8--55.93.9--88.0  95% CIs of mean27.4--29.628.1--31.427.3--30.428.1--29.7Day on which the depth of ANC nadir was reached  N298147144589  Mean (SD)7.1 (2.0)7.1 (0.6)7.2 (1.8)7.1 (1.7)  Median7.07.07.07.0  Minimum--maximum1--216--116--211--21  95% CIs of mean6.9--7.47.0--7.26.9--7.57.0--7.3Depth of ANC nadir (× 10^9^/L)  N298147144589  Mean (SD)0.6 (1.1)0.4 (0.6)0.4 (0.7)0.5 (0.9)  Median0.20.20.10.2  Minimum--maximum0.0--9.80.0--3.40.0--6.00.0--9.8  95% CIs of mean0.4--0.70.3--0.50.3--0.50.4--0.6 Day on which recovery of ANC was reached  N270135135540  Mean (SD)9.4 (2)9.4 (2.1)9.2 (1.0)9.4 (1.8)  Median9.09.09.09.0  Minimum--maximum6--258--228--136--25  95% CIs of mean9.2--9.79.1--9.89.0--9.49.2--9.5

Comparative safety {#Sec10}
------------------

The number of AEs in the three treatment arms were similar, and the majority were considered to be mild to moderate in severity (Table [5](#Tab5){ref-type="table"}). For this analysis, any subject receiving the proposed biosimilar in any cycle (regardless of randomization) was included in the APO-Peg arm. Out of 589 subjects across the treatment arms, *539* (91.5%) reported at least one AE in the treatment phase (89.7% in the APO-Peg arm; 94.8% in the US-Neulasta arm; 92.8% in the EU-Neulasta arm; Table [5](#Tab5){ref-type="table"}).Table 5Frequency of most common adverse events (≥ 5%) in treatment period---safety analysis set sensitivitySystem organ classPreferred termProposed biosimilar pegfilgrastim (APO-Peg) *N *= 329US-licensed pegfilgrastim reference product (US-Neulasta^®^) N = 135EU-approved pegfilgrastim reference product (EU-Neulasta^®^) N = 125Total\
N = 589Any AE295 (89.7)128 (94.8)116 (92.8)539 (91.5)Blood and lymphatic system disordersAll PTs185 (56.2)88 (65.2)73 (58.4)346 (58.7)Anaemia14 (4.3)8 (5.9)8 (6.4)30 (5.1)Febrile Neutropenia15 (4.6)7 (5.2)4 (3.2)26 (4.4)Leukocytosis22 (6.7)17 (12.6)13 (10.4)52 (8.8)Leukopenia63 (19.1)40 (29.6)41 (32.8)144 (24.4)Neutropenia169 (51.4)79 (58.5)63 (50.4)311 (52.8)Neutrophilia14 (4.3)13 (9.6)11 (8.8)38 (6.5)Thrombocytopenia12 (3.6)5 (3.7)16 (12.8)33 (5.6)Ear and labyrinth disordersAll PTs17 (5.2)11 (8.1)15 (12.0)43 (7.3)Vertigo17 (5.2)9 (6.7)14 (11.2)40 (6.8)Gastrointestinal disordersAll PTs176 (53.5)81 (60.0)79 (63.2)336 (57.0)Abdominal pain19 (5.8)8 (5.9)11 (8.8)38 (6.5)Abdominal pain Upper20 (6.1)12 (8.9)17 (13.6)49 (8.3)Constipation8 (2.4)5 (3.7)7 (5.6)20 (3.4)Diarrhoea54 (16.4)32 (23.7)34 (27.2)120 (20.4)Dyspepsia9 (2.7)8 (5.9)11 (8.8)28 (4.8)Nausea145 (44.1)67 (49.6)65 (52.0)277 (47.0)Stomatitis20 (6.1)10 (7.4)5 (4.0)35 (5.9)Vomiting44 (13.4)18 (13.3)27 (21.6)89 (15.1)General disorders and administration site conditionsAll PTs147 (44.7)71 (52.6)69 (55.2)287 (48.7)Asthenia81 (24.6)41 (30.4)31 (24.8)153 (26.0)Fatigue43 (13.1)18 (13.3)32 (25.6)93 (15.8)Malaise9 (2.7)8 (5.9)5 (4.0)22 (3.7)Oedema Peripheral15 (4.6)10 (7.4)9 (7.2)34 (5.8)Pyrexia22 (6.7)12 (8.9)18 (14.4)52 (8.8)Metabolism and nutrition disordersAll PTs28 (8.5)16 (11.9)26 (20.8)70 (11.9)Decreased Appetite12 (3.6)9 (6.7)17 (13.6)38 (6.5)Musculoskeletal and connective tissue disordersAll PTs166 (50.5)77 (57.0)80 (64.0)323 (54.8)Arthralgia13 (4.0)8 (5.9)10 (8.0)31 (5.3)Bone pain149 (45.3)71 (52.6)70 (56.0)290 (49.2)Myalgia28 (8.5)19 (14.1)15 (12.0)62 (10.5)Nervous system disordersAll PTs119 (36.2)63 (46.7)53 (42.4)235 (39.9)Dizziness68 (20.7)24 (17.8)21 (16.8)113 (19.2)Headache67 (20.4)38 (28.1)31 (24.8)136 (23.1)Hypoesthesia9 (2.7)9 (6.7)6 (4.8)24 (4.1)Respiratory, thoracic and mediastinal disordersAll PTs31 (9.4)16 (11.9)19 (15.2)66 (11.2)Oropharyngeal Pain14 (4.3)8 (5.9)6 (4.8)28 (4.8)Skin and subcutaneous tissue disordersAll PTs92 (28.0)45 (33.3)46 (36.8)183 (31.1)Alopecia78 (23.7)36 (26.7)37 (29.6)151 (25.6)Scar pain3 (0.9)0 (0.0)7 (5.6)10 (1.7)

Two of the most common AEs were neutropenia in (52.8% of subjects overall; 51.4% in the APO-Peg arm; 58.5% in the US-Neulasta arm; 50.4% in the EU-Neulasta arm) and nausea (47.0% of subjects overall; 44.1% in the APO-Peg arm; 49.6% in the US-Neulasta arm; 52.0% in the EU-Neulasta arm) (Table [5](#Tab5){ref-type="table"}). In addition, bone pain, a common event associated with pegfilgrastim \[[@CR12]\] thought to be directly related to treatment with filgrastim, occurred at a similar frequency in the three treatment groups (45.3% in the APO-Peg arm; 52.6% in the US-Neulasta arm; 56.0% in the EU-Neulasta arm; Table [5](#Tab5){ref-type="table"}) and none of these events were reported as a serious adverse event (SAE), or led to subject withdrawal.

One subject randomized to US-licensed pegfilgrastim reference product but receiving the proposed pegfilgrastim biosimilar died due to disease progression. Five additional life-threatening events were reported in the APO-Peg treatment arm (3 FN, 1 pancytopenia, and 1 pulmonary embolism). None of these events were related to the study drug. The incidence of immunogenicity was low and similar across treatment arms, including no apparent clinically meaningful effects associated with anti-drug antibodies (ADAs) or neutralizing antibodies (data not shown).

Discussion {#Sec11}
==========

The term *biosimilarity*, defined in section 351(i) of the Public Health Services (PHS) Act \[[@CR11]\], means that the biological product is "highly similar to the reference product notwithstanding minor differences in clinically inactive components; and there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product" \[[@CR12]\]. A demonstration that a product is biosimilar to its reference product is established analytically and then confirmed clinically in patients to show that the efficacy and safety profiles of the proposed biosimilar and reference product are comparable. This clinical confirmatory study is not meant to demonstrate the safety and efficacy of the biosimilar a priori, but to provide additional evidence that the proposed biosimilar and the reference product are similar giving the same clinical results as the reference biologic in a head-to-head study.

Building on prior work demonstrating that the Apotex/Intas proposed biosimilar pegfilgrastim is analytically highly similar to US-licensed pegfilgrastim \[[@CR8]\], as well similar with regards to PK/PD and safety in healthy volunteers \[[@CR9]\], results from this clinical confirmatory study in breast cancer patients further support the biosimilarity of the proposed biosimilar pegfilgrastim to the US-licensed and EU-licensed pegfilgrastim reference product.

The proposed biosimilar showed comparable mean DSN in Cycle 1 to both the US-licensed and EU-approved pegfilgrastim reference products, and the data are consistent with the published data for these reference products. While the 95% CI of the difference in mean DSN in Cycle 1 for the *As Randomized* population was slightly outside the pre-defined equivalence margin of ± 0.5 days, prior data suggest that this range is very conservative. An equivalence range of ± 1 day, consistent with the usual daily sampling of ANC, has commonly been used in other similar studies \[[@CR13], [@CR14]\]. Given that sampling of ANC for determination of DSN in a clinical setting is conducted on a daily basis, as in this study, the breach of 0.01 days, which equates to approximately 14.4 min from the upper limit of the equivalence range (0.51 days), is not considered clinically significant. In outpatient practice, neutrophils are measured on the day of chemotherapy administration, without considerations about when the nadir occurred, or recovery of ANC. Even in a hospitalized setting, with patients at risk of developing febrile neutropenia, and monitored daily, a difference of 14.4 min in DSN would not have any clinical impact.

The mean DSN in the absence of G-CSF in breast cancer patients treated with doxorubicin and docetaxel is expected to be 6--7 days \[[@CR15]\], while prophylactic treatment with a single fixed 6-mg dose of pegfilgrastim is expected to reduce the mean DSN in Cycle 1 to approximately 1.8 days \[[@CR14]\]. Thus, the treatment effect of pegfilgrastim in the reduction of the mean DSN in Cycle 1 can be expected to be between 4.2 and 5.2 days, and as such, an equivalence interval of ± 0.5 days should ensure that at least 88%--90% of the effect size (i.e., pegfilgrastim reduction in DSN) is retained, a more stringent requirement than typically applied in non-inferiority or equivalence studies.

Similarity between the proposed pegfilgrastim biosimilar and the US-licensed and EU-approved pegfilgrastim reference products was also supported by the results from all secondary efficacy analyses including the depth and peak of ANC nadir in Cycle 1, the time to ANC recovery post-nadir in Cycle 1, the rates of FN by cycle and across cycles, and the ANC time profile in Cycle 1.

The AE incidence was similar across treatment arms and there were no unexpected safety events for the proposed pegfilgrastim biosimilar. The incidence of immunogenicity was low and similar across treatment arms, including no apparent clinically meaningful effects associated with anti-drug antibodies (ADAs) or neutralizing antibodies. Overall, these results contribute to the totality of the evidence collected to support a conclusion of biosimilarity between the proposed biosimilar pegfilgrastim and the reference product. Just like originator biologics, post marketing surveillance data, from the countries where the product is approved, is being continually monitored and the results are no different from those found with other pegfilgrastim products.

Conclusions {#Sec12}
===========

This head-to-head, randomized, clinical confirmatory study of a proposed pegfilgrastim biosimilar demonstrates that the proposed pegfilgrastim is similar to Amgen's US-licensed and EU-approved pegfilgrastim reference products, with regard to safety and efficacy, in the treatment of chemotherapy-induced neutropenia in breast cancer patients receiving myelosuppressive chemotherapy.
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